Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2016-10-19 Investor Presentation
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
8-K 10.19.16
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 19, 2016. It includes a Regulation FD Disclosure of a slide presentation used at investor and industry conferences, attached as Exhibit 99.1. The text explicitly states that the presentation is attached and incorporated solely for disclosure purposes, and the report is not considered filed for certain regulatory liabilities. The document is short (2998 characters) and primarily serves to announce the availability of the investor presentation rather than containing the presentation itself or detailed financial data. According to the rules, such a document is best classified as an Investor Presentation (IP) since it involves a detailed presentation for investors focusing on financials, strategy, and market position, and is attached as an exhibit to the 8-K. The 8-K form itself is a regulatory filing but here it is used to disclose an investor presentation. Therefore, the classification is IP with high confidence.
2016-10-19 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-10-12 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-10-12 English
8-K 10.12.16
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated October 10, 2016, by Caladrius Biosciences, Inc. The key content is the appointment of a new board member, Dr. Gregory B. Brown, increasing the board size from eight to nine. It details his roles, compensation, and stock option grants. This is a clear announcement of a change in the company's board of directors. There is no financial data or report attached, and the document is not an earnings release or annual report. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3661 characters, which is consistent with a typical 8-K filing for management changes. Confidence is high due to explicit mention of board appointment and related details.
2016-10-12 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-09-30 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-09-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.